转移性结直肠癌中HER-2不同分类标准的判读及临床意义

Interpretation and clinical significance of different HER-2 classification standards in metastatic colorectal cancer

  • 摘要:
    目的 在抗体偶联药物(antibody drug conjugate,ADC)逐渐兴起的背景下,基于Hofmann标准与HERACLES标准,评估转移性结直肠癌(metastatic colorectal cancer,mCRC)中HER-2表达及临床意义。
    方法 回顾性收集2011年1月至2013年12月在天津医科大学肿瘤医院经明确病理诊断的mCRC患者的转移灶(105例)及对应原发灶组织(70例),应用两种标准对HER-2进行三分类(HER-2 0、HER-2低表达和HER-2阳性)评估,比较两种标准的一致性及配对转移灶与原发灶的一致性,并分析HER-2表达与临床病理因素的相关性。
    结果 基于两种标准,mCRC转移灶中HER-2阳性率均为3.8%(4/105),原发灶中的HER-2阳性率分别为7.1%(5/70)和5.7%(4/70)。不论原发灶还是转移灶,Hofmann标准对HER-2低表达患者的检出率均高于HERACLES标准(28.6% vs. 25.7%;20.0% vs. 11.4%)。两种标准评估HER-2表达的一致性较好(kappa=0.828)。不论基于何种评价标准,原发灶和转移灶中HER-2表达存在差异性(差异率28.6%)。
    结论 本研究发现mCRC中HER-2阳性及HER-2低表达在转移灶与原发灶之间均存在差异性,建议临床可以同时检测以提高检出率。Hofmann标准对HER-2低表达患者检出率高于HERACLES标准,鉴于目前对于CRC中HER-2表达尚无统一判读标准,ADC药物的临床疗效与不同判读标准下HER-2表达的关系还需要进一步大样本、多中心研究。

     

    Abstract:
    Objective Given the rising popularity of antibody-drug conjugate (ADC), this study was performed to assess the expression of human epidermal growth factor receptor 2 (HER-2) in metastatic colorectal cancer (mCRC) based on the Hofmann and HERACLES standards and to investigate its clinical significance.
    Methods We evaluated 105 metastatic lesions and corresponding primary tumor tissues from 70 patients diagnosed with mCRC at Tianjin Medical University Cancer Institute & Hospital from January 2011 to December 2013. We assigned each patient to one of the three HER-2 expression classifications (HER-2 absent, HER-2 low, and HER-2 positive) separately using Hofmann and HERACLES criteria. We compared the consistency of the two evaluation criteria and the results between matched metastatic lesions and primary tumors. We also analyzed the correlation between HER-2 expression and clinicopathological factors in the patients.
    Results HER-2 positivity rates based on Hofmann and HERACLES criteria were 3.8% (4/105) for metastatic lesions of mCRC and 7.1% (5/70) and 5.7% (4/70) for primary tumors, respectively. The detection rates of low HER-2 expression in both primary and metastatic lesions were higher with the Hofmann criteria (28.6% vs. 25.7%) than with the HERACLES criteria (20.0% vs. 11.4%) . The consistency of HER-2 expression assessment between the two criteria was good (kappa coefficient: 0.828). An inconsistency was observed in HER-2 expression between primary tumors and metastatic lesions (inconsistency rate, 28.6%).
    Conclusions The incidences of HER-2 positivity and low HER-2 expression were inconsistent between metastatic and primary lesions in mCRC, suggesting that clinical testing for both should be conducted simultaneously to improve the detection rates. The Hofmann criteria showed a higher detection rate for low HER-2 expression than that by the HERACLES criteria. Given the lack of a unified interpretation standard for HER-2 expression in CRC, the relationship between the clinical efficacy of ADC and HER-2 expression under different interpretation standards needs to be further evaluated in large-sample, multicenter studies.

     

/

返回文章
返回